BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  BioCapital

  J&J Suffers New Warning Label, Woodcock: “Most People are Going to Get COVID”

  The FDA informed Johnson & Johnson that adverse-event reports indicated a possible increased risk of immune thrombocytopenia within 42 days after vaccination with their COVID-19 vaccine.

  January 12, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Beyond COVID-19: the Potential of mRNA in Occupational Cancer

  According to the Environmental Litigation Group, P.C., approximately 37.5% of all occupational lung cancer cases are related to occupational asbestos exposure.

  January 12, 2022

   · 

  5 min read

   · 

  Kaylei Whalen
• 

  Business

  Daiichi Sankyo Shuttering Plexxikon Site in Favor of ADCs

  Daiichi wants to maximize its investment in three antibody-drug conjugates, which the company has positioned as one of the strategic pillars of its 5-year Business Plan.

  January 12, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Anticipating a Permanent Shift to Virtual, Pfizer will Reduce Sales Reps

  Pfizer is cutting its sales staff as physicians and healthcare facilities prefer fewer face-to-face interactions with vendors due to the COVID-19 pandemic.

  January 12, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Pardes Bio Allocating IPO Funds to Trial COVID-19 Drug, Ramp Up Staff

  Pardes is funneling the funds into financing the next stage of clinical trials and commercial production of its lead oral antiviral drug, PBI-0451, for the treatment and prevention of SARS-CoV-2 infections.

  January 12, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  BeyondSpring Cutting U.S. Workforce by 35% to Focus on High-Value Projects

  The job cuts were announced as part of an organizational streamlining initiative that will refocus resources toward the company’s highest-value activities.

  January 12, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Atai Gets Greenlight to Proceed with Treatment Resistant Depression Asset

  PCN-101 was recently awarded Investigational New Drug (IND) status by the U.S. Food and Drug Administration. It’s a for treating the patients with treatment resistant depression.

  January 12, 2022

   · 

  2 min read

   · 

  Kaylei Whalen
• 

  Drug Development

  Outsmarting Cancer: Next Generation Therapies

  Protein degradation, cell therapy, synergistic combinations and changes in personalized cancer therapies will drive the next generation of therapeutics...

  January 12, 2022

   · 

  4 min read

   · 

  Gail Dutton
• 

  Business

  Sanofi Goes All-In on Parkinson’s with “Groundbreaking” ABL Bio Deal

  Sanofi will pay ABL $75 million upfront, and the latter is eligible to receive as much as $985 million down the line as development, regulatory, and commercialization milestones are met.

  January 12, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  JPM Day 2: Amgen, GSK, 2seventy Bio Prepare for Transformative 2022

  BioSpace takes a look at the presentations made by Amgen, GSK and 2sevent bio at the all-virtual J.P. Morgan Conference.

  January 12, 2022

   · 

  4 min read

   · 

  Alex Keown